Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma

BMC Cancer

Volumn 13, Issue , 2013, Pages

  Wolf, Sanne E J ^a   Meenken, Christina ^a   Moll, Annette C ^a   Haanen, John B ^b   van der Heijden, Michiel S ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

BRAF; Melanoma; Uveitis; Vemurafenib

Indexed keywords

B RAF KINASE; PREDNISONE; VEMURAFENIB;

ADULT; ARTICLE; BONE BIOPSY; BRAF GENE; BRAIN METASTASIS; CANCER MORTALITY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; EYE EXAMINATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG METASTASIS; METASTATIC MELANOMA; MIDDLE AGED; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIORBITAL EDEMA; PERITONEUM METASTASIS; SCLERITIS; SPINE METASTASIS; UVEITIS; VISUAL IMPAIRMENT;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FATAL OUTCOME; FEMALE; HUMANS; INDOLES; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; SULFONAMIDES; UVEITIS;

EID: 84888379181     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-561     Document Type: Article

References (13)

1. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364(26):2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808.
2. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH, Kaempgen E, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380(9839):358-365. 10.1016/S0140-6736(12)60868-X, 22735384.
3. Robert C, Thomas L, Bondarenko I, O'Day S, DJ M, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364(26):2517-2526. 10.1056/NEJMoa1104621, 21639810.
4. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363(8):711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
5. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012, 367(18):1694-1703. 10.1056/NEJMoa1210093, 3549295, 23020132.
6. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012, 366(26):2443-2454. 10.1056/NEJMoa1200690, 3544539, 22658127.
7. Di Giacomo AM, Biagioli M, Maio M. The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol 2010, 37(5):499-507. 10.1053/j.seminoncol.2010.09.007, 21074065.
8. Sandhu S, Ling C, Lim L, Zamir E, Stawell R. Vemurafenib (B-RAF inhibitor) associated uveitis in patients with metastatic cutaneous melanoma. Clin Exp Ophth 2012, 40(S1):118.
9. Fraunfelder FW, Rosenbaum JT. Drug-induced uveitis. Incidence, prevention and treatment. Drug Saf 1997, 17(3):197-207. 10.2165/00002018-199717030-00005, 9306054.
10. London NJ, Garg SJ, Moorthy RS, Cunningham ET. Drug-induced uveitis. J Ophthalmic Inflamm Infect 2013, 3(1):43. 10.1186/1869-5760-3-43, 3637087, 23522744.
11. Gueudry J, LeHoang P, Bodaghi B. Anti-tumor necrosis factor-alpha agents in noninfectious uveitis. Dev Ophthalmol 2012, 51:63-78.
12. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behcet's disease: a comparative 4-week study. Rheumatology (Oxford) 2011, 50(3):593-597. 10.1093/rheumatology/keq366, 21097877.
13. Boyd KP, Vincent B, Andea A, Conry RM, Hughey LC. Nonmalignant cutaneous findings associated with vemurafenib use in patients with metastatic melanoma. J Am Acad Dermatol 2012, 67(6):1375-1379. 10.1016/j.jaad.2012.06.045, 22940405.